Margaret Faul

Margaret received her B.Sc. and M.Sc degrees from University College Dublin, Ireland. She received her Ph.D. degree in Synthetic Organic Chemistry from Harvard University with Professor David A. Evans. In 1993 Margaret joined the Chemical Process R&D group at Eli Lilly and Company and in 2003 went to Amgen Inc, in Thousand Oaks, CA where she is currently Vice President of Drug Substance Technologies within Process Development and Amgen Massachusetts Site Head.

Since joining Amgen in 2003 Margaret has held numerous positions of increasing responsibility including Executive Director of the Pivotal Drug Substance Technologies, Vice President of Drug Product Technologies, and Vice President of the Manufacturing and Clinical Supply Chain organization. She has supported the advancement of the Amgen portfolio from clinical through to commercial development and been instrumental in the integration of innovative technologies into the manufacturing network. Margaret has invested a significant effort in evolving a green and sustainable culture in the workplace and these efforts have been recognized by Amgen being a recipient of the Presidential Green Chemistry Challenge Award.

Margaret has a strong external scientific presence with ~100 publications in peer review journals. She is a Fellow of the American Chemical Society and an elected member of the National Academy of Engineering. She is a past chair of the Board of Directors of the International Consortium for Innovation and Quality in the Pharmaceutical Industry and a founding member of the Enabling Technologies Consortium. Margaret is currently the Editor-in-Chief of Organic Process R&D, she has been an associate editor for Organic Letters and is a member of the editorial boards for Science of Synthesis, Organic Syntheses, Synthesis and SynLett, and Tetrahedron and Tet Lett. In partnership with Thiéme and the Science of Synthesis she sponsors the Dr. Margaret Faul Award for Women in the Chemical Sciences.